Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771636 | 0.98 | HRH3 (0.42) | HRH3DPP7L3MBTL1MAPTMAPK1 | |
| SCHEMBL5839699 | 0.91 | OPRM1 (0.43) | HRH3DPP7L3MBTL1MAPTMAPK1 | |
| SCHEMBL8390873 | 0.91 | OPRM1 (0.43) | HRH3DPP7L3MBTL1MAPTMAPK1 | |
| SCHEMBL1615523 | 0.91 | OPRM1 (0.39) | HRH3DPP7OPRM1DPP4FAP | |
| SCHEMBL9417420 | 0.89 | OPRM1 (0.44) | HRH3DPP7L3MBTL1MAPTMAPK1 | |
| SCHEMBL3585121 | 0.86 | DPP7 (0.41) | DPP7SLC6A3SLC6A2 | |
| SCHEMBL486412 | 0.84 | DPP7 (0.44) | HRH3DPP7L3MBTL1MAPTMAPK1 | |
| SCHEMBL1615233 | 0.84 | OPRM1 (0.48) | MAPTOPRM1 | |
| SCHEMBL1614359 | 0.82 | OPRM1 (0.46) | MAPTOPRM1 | |
| SCHEMBL1615271 | 0.82 | OPRM1 (0.46) | MAPTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2055302-B1 | Method for the improvement of islet signaling in diabetes mellitus and for its prevention | ROYALTY PHARMA COLLECTION TRUST (US) | 2014-09-10 | — | — | EP | claimed |
| EP-1283735-B2 | METHOD FOR THE IMPROVEMENT OF ISLET SIGNALING IN DIABETES MELLITUS AND FOR ITS PREVENTION | ROYALTY PHARMA COLLECTION TRUST (US) | 2012-10-24 | — | — | EP | claimed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| EP-2200609-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2010-06-30 | — | — | EP | claimed |
| EP-1087991-B1 | PRODRUGS OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | PROSIDION LTD (GB) | 2009-09-02 | — | — | EP | claimed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | claimed |
| EP-1283735-B1 | METHOD FOR THE IMPROVEMENT OF ISLET SIGNALING IN DIABETES MELLITUS AND FOR ITS PREVENTION | PROSIDION LTD (GB) | 2008-12-31 | — | — | EP | claimed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2200609-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | HRH3 988/4885DPP7 6/4885L3MBTL1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.